

15 Aug 2021 | Analysis

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: a history of Alzheimer's drug development; BioNTech looks beyond COVID-19 vaccines; gene therapy setbacks for bluebird; new promise for Roche's Polivy in B-cell lymphoma; and rising US momentum for US drug price negotiations.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 13 August 2021, including: a history of Alzheimer's drug development; [BioNTech SE](#) looks beyond COVID-19 vaccines; gene therapy setbacks for [bluebird bio](#); new promise for [Roche Holding AG](#)'s Polivy in B-cell lymphoma; and US momentum for US drug price negotiation rises.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Alzheimer's Disease: Many Failures Before One Success](#)" - Scrip, 10 Aug, 2021.)

(Also see "[As Vaccine Revenues Flow In, BioNTech Makes Rapid Oncology Push](#)" - Scrip, 10 Aug, 2021.)

(Also see "[Bluebird Exits Europe, Casting Clouds Over Gene Therapy Commercial Effort](#)" - Scrip, 9 Aug, 2021.)

(Also see "[Roche's Polivy Set For Blockbuster Sales After Frontline Lymphoma Success](#)" - Scrip, 9 Aug, 2021.)

(Also see "[Biden Pitches Medicare Price Negotiations That Acknowledge R&D Costs, Allow 'Significant' Profits](#)" - Scrip, 12 Aug, 2021.)

[Click here to explore this interactive content online](#) 